Johannes Leierer

List of Publications by Year
in descending order

15 papers	**645** citations	840776 **11** h-index	1058476 **14** g-index
15 all docs	**15** docs citations	**15** times ranked	**1199** citing authors

#	Article	IF	Citations
1	Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia, 2019, 62, 1154-1166.	6.3	284
2	Renal micro<scp>RNA</scp>â€•and <scp>RNA</scp>â€profiles in progressive chronic kidney disease. European Journal of Clinical Investigation, 2016, 46, 213-226.	3.4	96
3	Considerable international variation exists in blood pressure control and antihypertensive prescriptionÂpatterns in chronic kidney disease. Kidney International, 2019, 96, 983-994.	5.2	51
4	Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrology Dialysis Transplantation, 2016, 31, 930-936.	0.7	37
5	Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells. American Journal of Physiology - Renal Physiology, 2019, 316, F449-F462.	2.7	37
6	Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. Scientific Reports, 2017, 7, 15160.	3.3	28
7	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) â€" Study Design and Baseline Characteristics. Kidney and Blood Pressure Research, 2018, 43, 181-190.	2.0	27
8	Empagliflozin Inhibits Basal and IL-1Î²-Mediated MCP-1/CCL2 and Endothelin-1 Expression in Human Proximal Tubular Cells. International Journal of Molecular Sciences, 2020, 21, 8189.	4.1	19
9	Effect of cyclosporine, tacrolimus and sirolimus on cellular senescence in renal epithelial cells. Toxicology in Vitro, 2018, 48, 86-92.	2.4	17
10	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. Diabetes and Vascular Disease Research, 2019, 16, 47-56.	2.0	17
11	Empagliflozin Inhibits IL-1Î²-Mediated Inflammatory Response in Human Proximal Tubular Cells. International Journal of Molecular Sciences, 2021, 22, 5089.	4.1	15
12	Computational Drug Screening Identifies Compounds Targeting Renal Age-associated Molecular Profiles. Computational and Structural Biotechnology Journal, 2019, 17, 843-853.	4.1	6
13	Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 6885.	4.1	6
14	Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease. JCI Insight, 2019, 4, .	5.0	5
15	Systems Medicine Derived Biomarkers to Assess How Canagliflozin Delays Progression of Diabetic Kidney Disease. Diabetes, 2018, 67, 1126-P.	0.6	0